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Chapter 3. EED Library as a Basis for
Systematic Reviews
3.1 Defining Systematic Review Question Priorities
Evidence related to any topic area and addressing questions raised in Table 2 has
potential to move the EED field forward. While an argument could be made to pursue any of the
topic areas/questions, we had to define a starting question to address and had to develop a
prioritization scheme given the importance of many of the topic areas/questions. Descriptive
epidemiology (topic area I in Table 2), for example, would certainly be useful to gauge the scope
of the problem, but would probably not produce useful recommendations. We considered
developing a review that considered EED as a dependent variable (i.e., an outcome) of
processes and risk factors (topic area II in Table 2). Such a characterization might be used to
develop preventive interventions for EED. We next formulated a model of EED as an event that
causes many injuries in the host (topic area III in Table 2), such as stunting and micronutrient
deficiencies. A review based on this model could be considered an analysis of its consequences
by focusing on host injuries and population impact. Biomarkers of EED as a subject for review
(topic area IV in Table 2) could provide a compendium of tools that could be used to detect
EED, and possibly to shed light on its origin. Consideration was additionally given to reporting
the clinical course and pathophysiology of EED (topic area V in Table 2), to summarize the state
of knowledge about cellular and organ processes that underlie its disease course. Finally, we
considered reviewing existing treatment or prevention interventions for EED (topic area VI in
Table 2).
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To provide direction for our initial efforts, we decided that it was important to select areas
in which a sufficient body of data is likely to exist. An additional attribute for a useful review is
that the resulting analysis can be used for disease control.
With these considerations in mind, we narrowed the set to four lead questions:
1.

What is the evidence that EED is caused by (an) identifiable pathogen(s),
microbial populations, environmental or other identifiable factors?

2.

What is the evidence that EED can be prevented by any interventions?

3.

What is the evidence that EED can be noninvasively diagnosed?

4.

What is the evidence regarding efficacy/effectiveness of treatment
interventions for EED?

Based on deliberations amongst the co-authors, and engagement with the Bill & Melinda
Gates Foundation, as well as discussions at the Gut Integrity Workshop held in Seattle,
Washington in December 2010, we focused on noninvasive diagnosis of EED as a priority
systematic review question.
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3.2 Determining Relevance to the Systematic
Review
We carefully considered the specifics of the review question and framed the question for
consistency with the Population Intervention Comparison Outcome (PICO) framework for
systematic review questions [99]:
What biomarkers or diagnostic tests 1 have been used to identify or have been shown to
be associated with mucosal dysfunction of the small intestine 2 or host inflammation 3 in
children under five years of age from developing-country settings 4?
For the purpose of this systematic review question, dysfunction was defined as
manifestation of increased small intestinal permeability, decreased absorption of nutrients,
enteric inflammation, or abnormal enterocyte metabolism or cell function. These conditions
could be present in children with environmental enteric dysfunction based on histology or
persistent diarrhea or those with malnutrition, or who were clinically asymptomatic. Evaluation of
asymptomatic or “normal” subjects without overt clinical evidence of enteric dysfunction or those
with acute diarrhea was of interest as long as they were evaluated for tests of mucosal small
intestinal dysfunction (e.g., endoscopy, histology, or markers of permeability or absorption from
serum, urine, or stool) or they were being tested in the same study as children with persistent
diarrhea. Gastrointestinal dysfunction or enteropathy related to celiac disease, cow's milk
protein allergy (CMPA), inflammatory bowel disease, or cystic fibrosis, as well as primary

1

Assessments of host biological materials or imaging assessments (e.g. radiologic) of the host.
Including increased small intestinal permeability, decreased absorption of nutrients, enteric
inflammation, or abnormal enterocyte metabolism or cell function among those with enteropathy (e.g.
environmental enteric dysfunction (EED) based on histology or persistent diarrhea) or children with
malnutrition or clinically asymptomatic children.
3
Laboratory confirmed generalized or tissue inflammation, but not necessarily specifically measuring gutspecific inflammation, e.g. C-reactive protein (CRP), IL-6.
4
Defined as low or middle income country as determined by World Bank or among marginalized or
indigenous populations in a developed country.
2
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immunodeficiency disorders (e.g., X-linked agammaglobulinemia, common variable
immunodeficiency, IgA deficiency, IgG subclass deficiency) were excluded from this systematic
review.
Studies that used tests or markers specifically related to small intestinal mucosal
function (except for the aforementioned excluded specific enteropathies) among children under
five years of age from a developing country setting were included. These tests include biopsy,
tests of nutrient absorption (e.g., iron absorption), tests of gut permeability and/or absorption
(e.g., D-xylose, lactulose:mannitol ratio [L:M]), and stool markers (e.g., fecal fat, reducing
substances). Articles describing tests or markers of systemic inflammation that can be affected
by mucosal intestinal function (e.g., IL-6, C-reactive protein (CRP), blood counts) were also
included as long as they were conducted: a) among children with EED or enteric dysfunction
consistent with EED (e.g., those with persistent diarrhea and without an excluded enteropathy),
b) among acute diarrhea or asymptomatic patients in a study that compared results to subjects
with a small intestinal mucosal disorder of interest, or c) in association with a test of mucosal
small intestinal function. Articles that were limited to tests of micronutrient status, celiac or
CMPA disease-specific tests, or tests for specific pathogens were excluded from the systematic
review.
We decided to restrict this analysis to articles published between 2000 and 2010 in the
interest of producing an expedited analysis of a well-defined literature set. We retain the ability
to apply this methodology to the literature identified for prior intervals. We also performed an
assessment of 10 references chosen at random that were published between 1990 and 1999 to
determine the scope of additional information that an analysis of the literature prior to our
restricted time block might provide (Appendix 3). Of the 10 articles, only one had a sample size
of 100 or more subjects under five years of age. Overall, these articles do not lend substantial or
novel data to content already derived from the 2000-2010 analysis.
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We acknowledge that delving back to prior decades could provide additional informative
data. This is especially true because much study regarding EED occurred in the 1970s and
1980s and waned in the subsequent decades, and because technology is not evolving rapidly in
this field. However, secular trends in socioeconomic, environmental, nutritional, and disease
conditions as well as improvements in laboratory, epidemiologic, and biostatical methods
complicate comparison of data across studies from different time periods. Also, earlier studies
focused on adults.
The team included analysts knowledgeable in German, French, Spanish, Italian, and
Portuguese; thus, we were able to thoroughly dissect articles in these languages. References in
other languages were excluded as we were not able to translate other languages in detail
sufficient for the purposes of thorough extraction and analysis.
A summary of inclusion/exclusion criteria and of the instructions given to analysts is
provided in Table 6.
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Table 6. Guidelines for systematic review inclusion/exclusion determination and data
extraction.
Biomarkers and Diagnostics Systematic Review Question:
What biomarkers or diagnostic tests1 have been used to identify or have been shown to be
associated with mucosal dysfunction2 of the small intestine or host inflammation3 in children
under five years of age from developing-country settings4?
1

Assessments of host biological materials or imaging (e.g., radiologic) assessments of the host.
Dysfunction can be related to increased small intestinal permeability, decreased absorption of
nutrients, enteric inflammation, or abnormal enterocyte metabolism or cell function among those
with enteropathy (e.g., EED based on histology, persistent diarrhea) or children with malnutrition
or clinically asymptomatic children.
3
Laboratory-confirmed generalized or tissue inflammation, but not necessarily specifically
measuring gut-specific inflammation (e.g. CRP, IL-6).
4
Developing-country setting is defined as a low- or middle-income country (as classified by
World Bank) or among indigenous populations in a developed country.
2

Excludable conditions (non-EED enteropathies)
Celiac disease, IBD, CMPA, cystic fibrosis (CF) (diagnosed by abnormal sweat test), as well as
primary immunodeficiency disorders (e.g., X-Linked agammaglobulinemia, common variable
immunodeficiency, IgA deficiency, IgG subclass deficiency) were not conditions of interest for
this review unless the following circumstances existed:
1.
The study had controls or other subjects of interest who underwent diagnostic tests that
are of interest to us (see "Category I Tests," below).
2.
The condition (i.e., celiac disease, CMPA, IBD) did not meet our systematic review
criteria for defining or diagnosing that condition. In other words, these disorders may have been
incorrectly diagnosed and could actually have been an enteric dysfunction of interest.
Asymptomatic children and children with acute diarrhea:
Evaluation of asymptomatic or ‘normal’ subjects without overt clinical evidence of enteropathy or
those with acute diarrhea was pertinent to our review as long as the included tests of mucosal
small intestinal dysfunction (e.g., endoscopy, histology, or serum, urine, or stool markers of
permeability or absorption). We were not interested in asymptomatic children or those with
acute diarrhea if tested for only systemic markers, unless they were tested in the same study as
children with EED or persistent diarrhea (PD). We were interested in the comparison of
systemic tests in patients who are asymptomatic and/or have acute diarrhea vs. PD. For
example, if a systemic marker was measured in subjects who were asymptomatic or had acute
diarrhea, we did not include these data. However, if these tests were also performed in a PD
group, then we included the data from all of these subjects— acute diarrhea, PD, and
asymptomatic subjects— taking care to separate findings by these categories.
We did not include references about children who presented with abdominal pain, vomiting,
anemia, rectal bleeding, gastroesophageal reflux, etc., unless they reported to have also had
EED, tropical enteropathy (TE), environmental enteropathy (EE), PD, malabsorption, or other
symptoms suggesting small intestinal mucosal dysfunction.
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Tests to Include:
Tests specific to intestinal dysfunction: We included biomarkers and diagnostic tests specifically
related to small intestinal mucosal function if other inclusion criteria were met (i.e., age under 5,
developing-country setting, etc.). We included these types of tests:
•
•
•

Endoscopy
Intestinal biopsy or lavage
Lactose/sucrose load test

Tests of nutrient absorption (not static blood levels; see Excludable Diagnostic Tests, below),
such as the following:
•
•
•
•

B12 absorption
Iron absorption
Calcium absorption
13
C sucrose or hydrogen breath test (HBT)

Urine markers of gut permeability or absorption:
•
•
•
•
•
•
•
•
•
•
•

D-xylose
Creatinine, fraction excretion
Lactulose, fraction excretion
Sucrose, fraction excretion
Sucralose, fraction excretion
Mannitol, fraction excretion
L:M (lactulose:mannitol) ratio
Sucrose:lactulose ratio
Sucralose:lactulose ratio
Urea:creatinine ratio
Lactose:creatinine ratio

Any stool markers (except those testing for specific micro-organisms; see Excludable Diagnostic
Tests, below), such as the following:
•
•
•
•
•
•
•
•
•
•
•

Alpha-1-antitrypsin
Calprotectin
Fecal fat
Lactoferrin
Neopterin
Myeloperoxidase
pH
Reducing substances
Leukocytes (i.e., white blood cells (WBCs) by microscopy
Occult blood testing (including guiac)
Red blood cells (RBCs) by microscopy

Systemic, Non-specific Tests: Many biomarkers and diagnostic tests, including the below list of
systemic markers of inflammation, can be impacted by mucosal intestinal function, but they can
also be impacted by other non-gastrointestinal disorders.
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For these tests, we only included if one or more of the following conditions were met:
1. They were conducted among patients with a mucosal small intestinal disorder of interest
(e.g., EED, PD, or among asymptomatic or acute diarrhea subjects in a study that also
examined subjects with mucosal small intestinal disorder of interest).
2. The tests were reported in relation to a test of mucosal small intestinal function (see list
above).
Examples of systemic, non-specific tests are the following:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Hemoglobin (HGB), hematocrit (HCT) (blood cell counts)
Total serum proteins and other serum proteins such as albumin, pre-albumin
Serum lipids and lipoproteins
Liver function tests (e.g., alanine transaminase)
Urine sodium (Na)
Urine pH
Systemic inflammatory markers such as:
C-reactive protein (CRP)
Erythrocyte sedimentation rate (ESR)
Tumor necrosis factor (TNF)
Interleukin-6 (IL-6)
Interferon-gamma (IFN-gamma)
Alpha-1-acid glycoprotein (AGP)
Serum immunoglobulins
Immune cell subsets
Ferritin

Algorithm for our inclusion/exclusion decisions on tests/markers:
1
Was the test performed on children under five years in a developing-country setting? If
no, exclude. If yes, continue.
2.

Is the test on the list of excludable tests? If yes, exclude. If no, continue.

3.
Is the test potentially related to small intestinal mucosal function? If no, exclude. If yes,
continue.
4.
Is the test specific for small intestinal mucosal function? If yes, include and extract data.
If no, continue.
5.
Is the test a more general test that could be related to dysfunction of other organ
systems? If no, exclude. If yes, continue.
6.
Was the test assessed among children with mucosal small intestinal dysfunction or
among children who have been assessed for mucosal small intestinal dysfunction? If no,
exclude. If yes, include and extract data.
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3.3 Acquisition of References and Copyright Fair
Use Compliance
References potentially relevant to the systematic review were determined by querying
the EED Library Access database. The query identified references tagged as explicitly EEDrelated and relevant to or possibly relevant to topic area IV (i.e., diagnostic tests and
biomarkers).
Starting in reverse chronological order, full texts of references that were identified as
potentially relevant to the systematic review were obtained as Portable Document Format files
(PDFs) and deposited into a central repository on Google Drive.
We maintained compliance with Fair Use obligations of U.S. Copyright Law,
watermarking all PDFs and making the Google Drive repository available only to team
members. Furthermore, analysts who performed data extraction indicated their compliance with
fair use when logging into the data entry system, via a checkbox that stated “I agree to use this
article according to US copyright law.”

3.4 Documenting Relevance to the Systematic
Review
Two principal investigators (DMD, PIT) and/or lead analysts (ZCN, KMV) reviewed
discordant decisions made by research analysts (RAs) to determine relevance of references to
the systematic review according to written guidelines (Table 6). In addition, a subset of
concordant decisions (with an emphasis on excluded references) was reviewed for quality
control.
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After the systematic search of the EED Library, we employed the "snowball technique" to
identify further articles relevant to the systematic review. The snowball technique involves
review of bibliographies of references determined as relevant to the systematic review, and
cited articles were cross-checked against the EED Library. If not already included in the Library,
the article was evaluated for inclusion in the Library and the systematic review.

3.5 Data Extraction for the Systematic Review
For data extraction, presentation, and analysis, we utilized the REDCap (Research
Electronic Data Capture) system (http://project-redcap.org/). REDCap is a secure, web-based
application for construction and management of online surveys and databases from multiple
users [100]. A sample REDCap template for data extracted from systematic review references
can be found in Appendix 4.
After inclusion/exclusion decisions for the review were finalized, six analysts extracted
data from studies into REDCap. The analysts were provided written guidelines on the type of
data to be extracted (Table 6). Conference call training sessions were employed to reinforce
guidelines and to address questions. Analysts were instructed to extract data on relevant facets
including: study objectives, outcome of relevance to review question, setting, study design,
subject description, case definition for subjects of interest, age groups and age range, study
population, sample size for review question, biomarkers or diagnostic tests, test conditions and
specifications, and results, as well as provide their impression of the evidence quality and a
study synopsis. Extracted data were reviewed for accuracy and completeness by lead analysts,
who made edits as needed and provided feedback to the RAs to increase efficiency and
accuracy.
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We exported specific fields of data from REDCap, facilitating analyses and data
presentation in evidence table format. From these characterizations, we portrayed the spectrum
of responses in quantitative and free-text formats as needed.
It is important to note that the EED Library, with references from PubMed, EMBASE,
Global Health, and WHO Regional databases that were published between 1980 and 2010,
remains available for research relevant to enteric dysfunction in children in resource-poor
environments.

3.6 EED Library: Search Results Overview
The systematic search of PubMed, Embase, WHO Regional, and Global Health
databases yielded 85,334 references of potential relevance to the EED Library. 17,431
references that were published before 1980 have not been assessed for inclusion in the Library.
67,903 references published between 1980 and 2010 are depicted in Figure 6. A small portion
of this set was not reviewed because full text was necessary for determination, but was not
available (i.e., we were unable to retrieve 89 articles published between 2000 and 2010).
66,541 references were dual-reviewed against EED Library inclusion criteria with 9,669
admitted to the project Library. Fifteen percent of those included were reviews, commentaries,
abstract proceedings, books, or editorials, and the remainder were references with primary data.
To conserve project resources, approximately 1,350 articles from the original systematic search
that were published before 2000 were not reviewed for library inclusion.
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Figure 6. Flowchart of project procedure results.

3.7 Quality Control
Accuracy and completeness in coding inclusion/exclusion and labels, tags, and topic
areas by analysts were closely monitored. Means for the percent of inaccurate exclusion and
inclusion and for kappa statistics were weighted based on the number of reference
spreadsheets reviewed by each analyst. The overall inaccurate exclusion and inclusion rates
were 2.2% and 2.7%, respectively. The kappa average for the group of analysts was 0.76,
which is considered to be in the "substantial concordance" range [98]. In addition, 1,200
references that were concordantly excluded by two analysts were reviewed by a lead analyst;
the exclusion error rate for these references was 0.5% (Table 7).
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Table 7. Accuracy rates for inclusion and exclusion.
Concordance/discordance between analysts and study investigators on an evaluation set of
12,000 references. Analysts who completed only a limited number of references are not
included.

Analyst

Inaccurate
Exclude
(%)

Inaccurate
Include (%)

Kappa
(mean)

Number of
references
analyzed
for quality
control

A

5.2

3.4

0.46

1800

B

0.9

3.2

0.83

11400

C

2.9

0.9

0.78

2000

D

1.9

2.9

0.78

7800

E

2.9

1.3

0.74

6400

F

5.8

6.4

0.50

600

G

6.4

3.7

0.61

200

H

2.9

3.3

0.75

600

I

4.2

6.5

0.67

800

J

3.3

0.7

0.79

600

Weighted
average
inaccurate
exclude
2.2

Weighted
average
inaccurate
include
2.7

Weighted
average
kappa

Concordant
exclusion
error rate

0.76

0.5 %

Group
metrics:

3.8 EED Library Status
Twenty percent of all of the references derived from our initial systematic search of the
PubMed, Embase, and Global Health databases were published between 2006 and 2010. The
discordance between the abundance of references that we found in our search and the paucity
of references found in the ISI query suggest that relevant literature is indexed with search terms
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that are neither sensitive nor specific. The inclusive approach using terms that broadened the
scope of papers identified was therefore warranted, even though such broadening obligated the
inclusion of over 85,000 references.
Furthermore, careful documentation of our search terms allows reproducibility despite
the complex nature of our strategy. The search strategy can be replicated and resultant
references run through our project procedures to update the Library at any time. In addition, the
search strategy designed for this project can be modified if related searches are needed.
The EED Library, as derived from PubMed, EMBASE, Global Health and WHO Regional
databases and published between 1980 and 2010, was designed to be a resource for scientists,
public health and clinical practitioners working on a variety of EED investigations. In fact, we
have interrogated our EED Library for several groups of researchers in the field:
1.

2.

3.
4.
5.

Dr. David Rudnick at Washington University in St. Louis requested assistance in
his work on liver function and growth in resource-limited settings, and we queried
the database as regards the role of aflatoxin and growth as reflected in the
literature.
We provided a list of references from the last decade that reported use of
biopsies among children in resource-limited settings to Dr. James Lavery‘s team
in Toronto to assist in their examination of ethical considerations of invasive and
noninvasive assessments of what they termed "tropical enteropathy/enteric
enteropathy."
We provided data from our database to Dr. Gerald Keusch’s team (which
includes co-authors Drs. Denno and Tarr) who were building a working definition
of EED.
The master evidence table was made available to all of the participants of the Bill
and Melinda Gates Foundation Grand Challenges Gut Function Biomarker
Shaping Meeting in London in June 2012.
We performed a pilot project for the Bill and Melinda Gates Foundation to
determine the number of studies in the EED database that involved interventions.
We further determined how many of these were clinical trials vs. treatment
studies, categorized the interventions, and tallied the number of studies per
category.

The EED Library can be searched using the codes, labels and tags that our Research
Analyst team assigned to EED Library records. Continued assembly of literature post-2010
would add value if the database is to be further utilized to address other queries.
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